Description
Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer’s disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors.
Copyright Statement
Reuse Permissions
Download count: 0
Details
Contributors
- Hughes, Alexa (Author)
- Cichacz, Zbigniew (Author)
- Scheck, Adrienne (Author)
- Coons, Stephen W. (Author)
- Johnston, Stephen (Author)
- Stafford, Phillip (Author)
- Biodesign Institute (Contributor)
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)
2012-07-16
Resource Type
Collections this item is in
Identifier
- Digital object identifier: 10.1371/journal.pone.0040201
- Identifier Value1045-3830
-
Note
- The article is published at http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040201, opens in a new window
Citation and reuse
Cite this item
This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.
Hughes, A. K., Cichacz, Z., Scheck, A., Coons, S. W., Johnston, S. A., & Stafford, P. (2012). Immunosignaturing Can Detect Products from Molecular Markers in Brain Cancer. PLoS ONE, 7(7). doi:10.1371/journal.pone.0040201